Increasing demand for personalised treatments, an ageing population, the rise of new manufacturing technologies and 鈥榙igital鈥 medicines (drugs with an ingestible sensor embedded in them), are some of the primary growth opportunities for UK pharmaceuticals companies according to a new report from Santander and manufacturing organisation EEF1.